NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology
Excerpt from the Press Release:
BOSTON, April 15, 2021 /PRNewswire/ — NanoView Biosciences Inc. (“NanoView”), a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center (“BIDMC”) to study the involvement of biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (“ICIT”) for cancer. The ExoPD-L1 to Predict Immunotherapy Response in Cancer (“EPIC”) Study will specifically investigate Programmed Death-Ligand 1 (“PD-L1”) and status of disease as well as response to therapy.
Exosomes are small extracellular vesicles, 50 – 150 nm in size, that facilitate communication between cells by shuttling proteins, lipids and nucleic acids. NanoView’s platform technology, ExoView®, will be used in the EPIC Study to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing ICIT.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?